Anton Rx Report

The rumors about a big divestiture move by Centene Corp. finally materialized last week. Centene announced that they are spinning off both its PantherRx Rare

Over the years few new specialty therapies have been approved for Cardiology conditions. That may be about to finally change with a recent FDA approval.

We’ve written frequently on two of the biggest trends in channel access, the shift away from buy-and-bill to other, less costly, sites of service as

Limited distribution (LD) has contributed to the growth of a couple dozen specialty pharmacies over the past decade. When a pharmaceutical manufacturer selects a specialty pharmacy

Option Care Health announced that it has acquired the Specialty Pharmacy Nursing Network (SPNN) for $60 million in an all-cash transaction. SPNN will maintain its

The FDA approved the 35th biosimilar last week, Alymsys (bevacizumab-maly) from Amneal Pharmaceuticals, for seven cancer indications of the reference product, Avastin from Genentech. It

The National Home Infusion Association (NHIA) recently published the results of a survey of patients who had received a home chemotherapy infusion to gauge their

Last week the FDA approved a new ORAL specialty therapy, Vijoice (alpelisib) from Novartis Pharmaceuticals, indicated for breast cancer patients with evidence of mutation in

The FDA recently approved Opdualag (nivolumab and relatlimab-rmbw) from Bristol Myers Squibb, a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and

HIPAA…. the lurking threat to every specialty pharmacy. That’s a provocative statement….. but one that rings all too true. Each year we hear of yet